When cancer patients describe their experiences, they say: "\[information\] wasn't explained to me...you have to seek it out yourself", "it felt like they'd give you just enough information to go away with and then move on to the next patient", and "I didn't know what to expect when I went home". 99% of cancer care occurs in patients' homes. Patients only get information and advice from clinicians in short, infrequent appointments. Therefore, patients must learn for themselves how best to manage their health. But the information they need is spread out across many charities, websites and publications. Often, this information is inconsistent and confusing.[][0] Better information is also urgently needed by drug companies. Following recent regulatory changes, pharmaceutical companies must collect patient-reported information on safety and effectiveness of their cancer drugs. They are struggling to collect these data.[][1] Pharmaceutical companies, clinicians and charities understand this situation is unacceptable and worsens cancer outcomes but do not have the remit, resources or technical skills to collaborate effectively to improve it. As a small, experienced, credible and trusted technology company, Vinehealth meets the needs of patients and drug companies for better information; already leading this via partnerships across the fragmented cancer care ecosystem. Vinehealth's digital tools combine behavioural science and AI to improve cancer patient QoL, and collect patient-reported outcome (PRO) data that drug companies need. The platform is co-developed with patients, leading UK oncologists, all major UK cancer charities, and the most significant pharmaceutical companies. Vinehealth includes a patient-facing mobile app that delivers personalised information and support to enable cancer patients to better self-manage their medications, side-effects, symptoms and lifestyles, seamlessly integrating with smartphones and wearables. Patients can regularly enter PRO data to drive clinical research, inform clinical service re-design and provide pharma with crucial PRO data. PRO data can increase cancer survival up to 20%. Feasibility of the tool has been confirmed in UK's leading cancer centre (Royal Marsden). For commercial success, we must now finalise Vinehealth technical development and deliver a large randomised controlled trial over four NHS Trusts, generating robust evidence for Vinehealth's clinical and cost effectiveness in improving patient self-management and data collection. Technical work to prepare for the trial includes ensuring Vinehealth meets the NHS sites' data governance and interoperability requirements and further developing the platform for more personalised psychological support and broader PRO measures. [0]: https://paperpile.com/c/H8DKSw/hrbH [1]: https://paperpile.com/c/H8DKSw/HQom